1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Strategy

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+

 
• By Malcolm Spicer

A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.

ChromaDex rolled out Rx nicotinamide adenine dinucleotide products in August, along with a test kit for providers and consumers. (Source: CHromaDex)
Key Takeaways
  • Firm said its corporate name will be Niagen Bioscience Inc. starting on 19 March

ChromaDex Corp. is changing its name to better reflect its transition from relying on revenues from nicotinamide adenine dinucleotide (NAD+)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

AstaReal Launches Membralife Supplement Following CEO Change

 
• By Tom Gallen

Designed to help moisturize the body’s mucous membranes, the Membralife supplement is now available in Sweden. The launch comes with AstaReal now under new management following the appointment of Daniel Flodqvist as CEO.

People On The Move: Appointments At Kenvue, EFSA, FSE

 
• By Tom Gallen

A round-up of the latest people moves: Kenvue names APAC president; EFSA nominates executive director; Food Supplements Europe elects board.

Danone Acquires Belgian Firm Marketing Gut Health Supplement in US

 
• By Tom Gallen

Danone moves into dietary supplements space with deal for The Akkermansia Company marketing patented biotic strain in US, Europe and Asia.

Valbiotis Launches Plant-Based Heart Health Supplement

 
• By Tom Gallen

Available in French pharmacies and online, ValbiotisPRO Cardio-circulation comprises a blend of six plant extracts and is targeted at those with high blood pressure.

More from HBW Insight

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By David Ridley

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”